Regenetek Research Inc. is conducting research in a Case Study Series under the terms of Institutional Review Board sanction (with IRB approval through the DCG (India), IECP, (India), ICMR (India) (IRB File No. ECR/44/IECP/27/2011), and as of March 16, 2014, Institutional Review Board approval has been granted by the US-based International Cell Surgical Society (ICSS) (Approval # ICSS-2014-004), with patients who qualify studied for a period of 5-years. The study entitled ‘Intravenous and Intrathecal Implantation of Adult Autologous Stem Cells for Patients with Multiple Sclerosis and Other Neurodegenerative Diseases’ is an investigation of a novel, sequenced therapeutic strategy that considers both the vasculature and central nervous system in a treatment with adult autologous stem cells (cells taken from the patient). Based on what has been established as evidence in previous investigations into neurodegenerative diseases through clinical trials, this protocol was developed over several years- 2009 through 2011. The study was approved on June 16, 2011 by the IECP and patient therapies began in August, 2011.

Channel-Art-Template2
“Stem cell research is the key to developing cures for degenerative conditions like Parkinson’s and motor neurone disease from which I and many others suffer.”Stephen Hawking
Private Patient Resource Center

Ask for information

Applicants who qualify will be asked to participate in a long-term study with follow-up features that are a requirement of entry into the program. It is within the purview of the study to examine outcomes in all stages of the disease. This includes disability levels of the disease from 2.0 through to 9.0 EDSS.

Contact Us